Related Experiment Videos
Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome
K E Towbin1, E M Dykens, R G Pugliese
1George Washington University School of Medicine, Washington, DC.
Insights
This study details the effective and safe use of clozapine in a child with early-onset schizophrenia, noting symptom improvement and reduced tardive dyskinesia. A slower dose titration was key for this pediatric patient.
Area of Science:
- Child and Adolescent Psychiatry
- Pharmacotherapy
- Neuroscience
Background:
- Childhood-onset schizophrenia (COS) presents unique treatment challenges.
- Limited data exists on atypical antipsychotic use in pediatric populations.
- Clozapine, an atypical antipsychotic, has shown efficacy in adult schizophrenia but is less studied in children.
Observation:
- A case report detailing the pharmacotherapy and long-term follow-up of a child treated with clozapine.
- The patient exhibited early social and developmental delays preceding schizophrenia diagnosis.
- This represents one of the earliest documented experiences with clozapine in pediatric patients in the United States.
Findings:
- Clozapine demonstrated relative effectiveness and safety in the pediatric patient.
- Significant improvement in symptoms of childhood-onset schizophrenia was observed.
- A notable reduction in tardive dyskinesia symptoms occurred during clozapine treatment.
- Slower dose escalation, compared to adult protocols, was crucial for tolerability.
Implications:
- This case highlights the potential utility of clozapine in managing severe childhood-onset schizophrenia.
- Findings suggest careful, slow dose titration is essential for pediatric clozapine therapy.
- The study contributes valuable early data on clozapine's use and safety profile in children.
Abstract:
This paper reports on the pharmacotherapy and long-term follow-up of a child treated with clozapine. It is one of the earliest American experiences with this agent in children to date. Clozapine was relatively effective and safe in this patient. Additional features of the case are the early social and developmental delays preceding schizophrenia, the response of symptoms of childhood-onset schizophrenia to clozapine, and the reduction in tardive dyskinesia symptoms while taking clozapine. Compared to recommendations for dosing adults, a slower rate of increasing clozapine doses was important for this child. For future reference, the protocol and consent form used for this course of treatment are included.